RxDoctor Payments Data

Deborah Wu, MD

Ophthalmology · Ludington, MINPI 1760698245

Payments from drug & device makers

$3,075in general payments, 2019–2025

Across 97 payments — averaging $31.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biotissue Holdings Inc.$722
  • Amgen$595
  • Alcon$510
  • Ocular Therapeutix, Inc.$234
  • AbbVie$152
  • Regeneron Healthcare Solutions, Inc.$152
  • plus $710 from 12 others

What the payments were for

  • Food & beverage$3,075100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,075 in reported general payments places this provider in the 70th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$183,184
Medicare patients
361
Services billed
2,360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj20$1,005,933
RestasisCyclosporine158$166,318
LumiganBimatoprost77$26,395
Cyclosporine55$23,529
CombiganBrimonidine Tartrate/Timolol41$12,528
RocklatanNetarsudil Mesylat/Latanoprost31$10,158
Restasis MultidoseCyclosporine14$9,436
TobradexTobramycin/Dexamethasone36$9,247
Prednisolone Acetate183$8,695
SimbrinzaBrinzolamide/Brimonidine Tart21$6,839
Latanoprost395$6,696
VyzultaLatanoprostene Bunod17$6,015
Travoprost23$4,160
Timolol Maleate211$3,434
Ketorolac Tromethamine136$2,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$92$1,005,93320 claims
AbbVieRestasis, Lumigan, Combigan, Restasis Multidose$152$214,677290 claims
Aerie Pharmaceuticals, Inc.Rocklatan$21$10,15831 claims
AlconSimbrinza$510$6,83921 claims
Bausch & Lomb Americas Inc.Vyzulta$19$6,01517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Ludington

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →